3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Neoplasms
2
Mycosis Fungoides
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Interventions
Nivolumab
114
Ipilimumab
114
pembrolizumab
108
aldesleukin
76
Cyclophosphamide
70
fludarabine phosphate
51
Interleukin-2
48
Temozolomide
41
Dacarbazine
36
trametinib
33
dabrafenib
30
Bevacizumab
30
sargramostim
29
Radiotherapy
29
incomplete Freund's adjuvant
27
fludarabine
27
Vemurafenib
25
Radiosurgery
25
Carboplatin
25
Paclitaxel
23
binimetinib
22
Biopsy
22
CTLA-4 Antigen
21
Peripheral Blood Stem Cell Transplantation
20
encorafenib
19
cemiplimab
19
atezolizumab
19
Mycophenolic Acid
19
HhAntag691
19
Aminolevulinic Acid
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
cobomarsen
×
Dermatologic
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled